Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

@article{McKenney2012SafetyAE,
  title={Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.},
  author={James M. McKenney and Michael Koren and Dean J Kereiakes and Corinne Hanotin and Anne-Catherine Ferrand and Evan A. Stein},
  journal={Journal of the American College of Cardiology},
  year={2012},
  volume={59 25},
  pages={2344-53}
}
OBJECTIVES The primary objective of this study was to evaluate the low-density lipoprotein cholesterol (LDL-C)-lowering efficacy of 5 SAR236553/REGN727 (SAR236553) dosing regimens versus placebo at week 12 in patients with LDL-C ≥100 mg/dl on stable atorvastatin therapy. Secondary objectives included evaluation of effects on other lipid parameters and the attainment of LDL-C treatment goals of <100 mg/dl (2.59 mmol/l) and <70 mg/dl (1.81 mmol/l). BACKGROUND Serum proprotein convertase… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 170 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Early studies of REGN727/SAR236553, a monoclonal antibody

  • EA Stein, S Mellis, GD Yancopoulos
  • JACC Vol. xx, No. x,
  • 2012
2 Excerpts

Effect of a monoclonal antibody to PCSK 9 on LDL cholesterol

  • JA Carlson, LF Cavaliere, JM Grant-Kels
  • N Engl J Med
  • 2012

ESC / EAS Guidelines for the management of dsylipi - daemias

  • C Baigent, A Keech, PM Kearney
  • Eur Heart J
  • 2011

REGN727/SAR236553, a fully human proprotein convertase subtilisin kexin 9 (PCSK9) monoclonal antibody: effects on safety and lipid and lipoprotein profiles when administered subcutaneously

  • G Swergold, S Biedermann, R Renard
  • J Am Coll Cardiol
  • 2011

Efficacy and safety of more intensive lowering of LDL cholesterol : a meta - analysis of data from 170 000 participants in 26 randomised trials

  • CP Cannon, BA Steinberg, SA Murphy, JL Mega, E Braunwald
  • Lancet
  • 2010

Similar Papers

Loading similar papers…